Senores Pharmaceuticals Limited has informed the Exchange regarding outcome of Board Meeting held on May 14, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported strong FY2026 annual results with consolidated revenue of Rs 632.63 Crores (up 82% from Rs 346.94 Crores), profit before tax of Rs 159.10 Crores (up 125% from Rs 70.57 Crores), and net profit of Rs 121.53 Crores (up 108% from Rs 58.34 Crores). Standalone revenue stood at Rs 106.09 Crores with net profit of Rs 20.26 Crores. The auditors issued an unmodified (clean) opinion on both consolidated and standalone financial statements. The Board also noted the resignation of Company Secretary Vinay Kumar Mishra effective June 10, 2026, and appointed Sharp & Tannan Associates as Internal Auditor for FY 2026-27. The company had listed via IPO in December 2024 and made a strategic acquisition of 75% stake in Apnar Pharma in January 2026.
Strong financial performance with near doubling of profitability demonstrates operational strength. The resignation of the Company Secretary creates a compliance vacuum ahead of the effective date, requiring immediate board attention. Growth trajectory appears robust with multiple subsidiaries and expanded operations.